These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 34384788)

  • 1. Nonalcoholic fatty liver disease stratification by liver lipidomics.
    Vvedenskaya O; Rose TD; Knittelfelder O; Palladini A; Wodke JAH; Schuhmann K; Ackerman JM; Wang Y; Has C; Brosch M; Thangapandi VR; Buch S; Züllig T; Hartler J; Köfeler HC; Röcken C; Coskun Ü; Klipp E; von Schoenfels W; Gross J; Schafmayer C; Hampe J; Pauling JK; Shevchenko A
    J Lipid Res; 2021; 62():100104. PubMed ID: 34384788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis.
    Ooi GJ; Meikle PJ; Huynh K; Earnest A; Roberts SK; Kemp W; Parker BL; Brown W; Burton P; Watt MJ
    J Hepatol; 2021 Sep; 75(3):524-535. PubMed ID: 33887358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver.
    Wang ZH; Zheng KI; Wang XD; Qiao J; Li YY; Zhang L; Zheng MH; Wu J
    Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):452-459. PubMed ID: 34256994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
    Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
    Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitochondrial dysfunction-related lipid changes occur in nonalcoholic fatty liver disease progression.
    Peng KY; Watt MJ; Rensen S; Greve JW; Huynh K; Jayawardana KS; Meikle PJ; Meex RCR
    J Lipid Res; 2018 Oct; 59(10):1977-1986. PubMed ID: 30042157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting Non-Alcoholic Steatohepatitis: A Lipidomics-Driven Machine Learning Approach.
    Mouskeftara T; Kalopitas G; Liapikos T; Arvanitakis K; Germanidis G; Gika H
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased diacylglycerols characterize hepatic lipid changes in progression of human nonalcoholic fatty liver disease; comparison to a murine model.
    Gorden DL; Ivanova PT; Myers DS; McIntyre JO; VanSaun MN; Wright JK; Matrisian LM; Brown HA
    PLoS One; 2011; 6(8):e22775. PubMed ID: 21857953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipidomic and transcriptomic analysis of western diet-induced nonalcoholic steatohepatitis (NASH) in female Ldlr -/- mice.
    Garcia-Jaramillo M; Spooner MH; Löhr CV; Wong CP; Zhang W; Jump DB
    PLoS One; 2019; 14(4):e0214387. PubMed ID: 30943218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipidomics in Nonalcoholic Fatty Liver Disease: Exploring Serum Lipids as Biomarkers for Pediatric Nonalcoholic Fatty Liver Disease.
    Draijer LG; Froon-Torenstra D; van Weeghel M; Vaz FM; Bohte AE; Holleboom AG; Benninga MA; Koot BGP
    J Pediatr Gastroenterol Nutr; 2020 Oct; 71(4):433-439. PubMed ID: 32947564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovering a critical transition state from nonalcoholic hepatosteatosis to nonalcoholic steatohepatitis by lipidomics and dynamical network biomarkers.
    Sa R; Zhang W; Ge J; Wei X; Zhou Y; Landzberg DR; Wang Z; Han X; Chen L; Yin H
    J Mol Cell Biol; 2016 Jun; 8(3):195-206. PubMed ID: 26993042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
    McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
    JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Pilot Study of Serum Sphingomyelin Dynamics in Subjects with Severe Obesity and Non-alcoholic Steatohepatitis after Sleeve Gastrectomy.
    Ramos-Molina B; Castellano-Castillo D; Pastor O; Ocaña-Wilhelmi L; Fernández-García D; Romero-Gómez M; Cardona F; Tinahones FJ
    Obes Surg; 2019 Mar; 29(3):983-989. PubMed ID: 30488259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum lipids are associated with nonalcoholic fatty liver disease: a pilot case-control study in Mexico.
    Flores YN; Amoon AT; Su B; Velazquez-Cruz R; Ramírez-Palacios P; Salmerón J; Rivera-Paredez B; Sinsheimer JS; Lusis AJ; Huertas-Vazquez A; Saab S; Glenn BA; May FP; Williams KJ; Bastani R; Bensinger SJ
    Lipids Health Dis; 2021 Oct; 20(1):136. PubMed ID: 34629052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating lipidomic alterations in obese and non-obese subjects with non-alcoholic fatty liver disease.
    Jung Y; Lee MK; Puri P; Koo BK; Joo SK; Jang SY; Lee DH; Jung YJ; Kim BG; Lee KL; Park TS; Kang KT; Ryu DH; Kang SW; Kim D; Oh S; Kim W; Hwang GS
    Aliment Pharmacol Ther; 2020 Nov; 52(10):1603-1614. PubMed ID: 32892365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A lipidomic analysis of nonalcoholic fatty liver disease.
    Puri P; Baillie RA; Wiest MM; Mirshahi F; Choudhury J; Cheung O; Sargeant C; Contos MJ; Sanyal AJ
    Hepatology; 2007 Oct; 46(4):1081-90. PubMed ID: 17654743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver lipidome signature and metabolic pathways in nonalcoholic fatty liver disease induced by a high-sugar diet.
    Oliveira DT; Chaves-Filho AB; Yoshinaga MY; Paiva NCN; Carneiro CM; Miyamoto S; Festuccia WT; Guerra-Sá R
    J Nutr Biochem; 2021 Jan; 87():108519. PubMed ID: 33017610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipidomics in pathogenesis, progression and treatment of nonalcoholic steatohepatitis (NASH): Recent advances.
    Musso G; Saba F; Cassader M; Gambino R
    Prog Lipid Res; 2023 Jul; 91():101238. PubMed ID: 37244504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ectodysplasin A Is Increased in Non-Alcoholic Fatty Liver Disease, But Is Not Associated With Type 2 Diabetes.
    Bayliss J; Ooi GJ; De Nardo W; Shah YJH; Montgomery MK; McLean C; Kemp W; Roberts SK; Brown WA; Burton PR; Watt MJ
    Front Endocrinol (Lausanne); 2021; 12():642432. PubMed ID: 33746906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
    Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adipose tissue insulin resistance and lipidome alterations as the characterizing factors of non-alcoholic steatohepatitis.
    Guerra S; Mocciaro G; Gastaldelli A
    Eur J Clin Invest; 2022 Mar; 52(3):e13695. PubMed ID: 34695228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.